The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
Open accessAbstract
Background: The ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We have previously shown that it is possible to achieve this in real time to impact public health decision making. Aim: Our objective was to develop and evaluate serological assays applicable in large-scale sero-epidemiological studies. Methods: We developed an ELISA to detect IgG and IgM antibodies to the receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated its sensitivity and specificity in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT 90) in 51 sera from 24 patients with virologically confirmed COVID-19 and in age-stratified sera from 200 healthy controls. Results: IgG and IgM RBD ELISA, MN and PRNT 90 were reliably positive after 29 days from illness onset with no detectable cross-reactivity in age-stratified controls. We found that PRNT 90 tests were more sensitive in detecting antibody than MN tests carried out with the conventional 100 tissue culture infectious dose challenge. Heparinised plasma appeared to reduce the infectivity of the virus challenge dose and may confound interpretation of neutralisation test. Conclusion: Using IgG ELISA based on the RBD of the spike protein to screen sera for SARS-CoV-2 antibody, followed by confirmation using PRNT 90, is a valid approach for large-scale sero-epidemiology studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
REED, L. J., & MUENCH, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 19,926
A simple method of estimating 50 per cent end points
Muench, H. (1938) · Medical Entomology and Zoology · Cited by 8,376
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,463
Self-citationA Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
Ekiert, D. C., Friesen, R. H. E., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H. J. W. M., Brandenburg, B., et al. (2011) · Science · doi:10.1126/science.1204839 · Cited by 822
Self-citationZhang, B., Zhou, X., Zhu, C., Song, Y., Feng, F., Qiu, Y., Feng, J., Jia, Q., Song, Q., Zhu, B., et al. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00157 · Cited by 528
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015
Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2307.170310 · Cited by 227
Self-citation2019-Novel Coronavirus (2019-nCoV): estimating the case fatality rate – a word of caution
Battegay, M., Kuehl, R., Tschudin-Sutter, S., Hirsch, H. H., Widmer, A. F., & Neher, R. A. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20203 · Cited by 199
The Infection Attack Rate and Severity of 2009 Pandemic H1N1 Influenza in Hong Kong
Wu, J. T., Ma, E. S. K., Lee, C. K., Chu, D. K. W., Ho, P., Shen, A. L., Ho, A., Hung, I. F. N., Riley, S., Ho, L. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/656740 · Cited by 191
Self-citation
Cited by
Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A. J., Cornaby, C., Bartelt, L., Weiss, S., Park, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc8413 · Cited by 868
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis
Lisboa Bastos, M., Tavaziva, G., Abidi, S. K., Campbell, J. R., Haraoui, L.-P., Johnston, J. C., Lan, Z., Law, S., MacLean, E., Trajman, A., et al. (2020) · BMJ · doi:10.1136/bmj.m2516 · Cited by 832
Virology, transmission, and pathogenesis of SARS-CoV-2
Cevik, M., Kuppalli, K., Kindrachuk, J., & Peiris, M. (2020) · BMJ · doi:10.1136/bmj.m3862 · Cited by 732
Self-citationLa Marca, A., Capuzzo, M., Paglia, T., Roli, L., Trenti, T., & Nelson, S. M. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.06.001 · Cited by 389
Cheng, S. M. S., Mok, C. K. P., Leung, Y. W. Y., Ng, S. S., Chan, K. C. K., Ko, F. W., Chen, C., Yiu, K., Lam, B. H. S., Lau, E. H. Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01704-7 · Cited by 361
Self-citation
Metadata
- Authors
- Perera, R. A., Mok, C. K., Tsang, O. T., Lv, H., Ko, R. L., Wu, N. C., Yuan, M., Leung, W. S., Chan, J. M., Chik, T. S., Choi, C. Y., Leung, K., Chan, K. H., Chan, K. C., Li, K.-C., Wu, J. T., Wilson, I. A., Monto, A. S., Poon, L. L., & Peiris, M.
- Venue
- Eurosurveillance
- Published
- 2020-04-23
- Volume
- 25
- Issue
- 16
- ISSN
- 1025-496X (ISSN-L)
- 1560-7917
- OpenAlex
- W3017962953
- Cited by
- 322
- References
- 16
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. https://app.cochat.ai/papers/10.2807/1560-7917.es.2020.25.16.2000421
- The paper
- Perera, R. A., Mok, C. K., Tsang, O. T., Lv, H., Ko, R. L., Wu, N. C., Yuan, M., Leung, W. S., Chan, J. M., Chik, T. S., Choi, C. Y., Leung, K., Chan, K. H., Chan, K. C., Li, K.-C., Wu, J. T., Wilson, I. A., Monto, A. S., Poon, L. L., & Peiris, M. (2020). Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance. https://doi.org/10.2807/1560-7917.es.2020.25.16.2000421
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
